NCT02910492已完成不适用
A Single-Center, Open-Label Exploratory Study of a Novel Laser for Skin Rejuvenation
Cutera Inc.2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2016年9月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Degree of Improvement as Assessed by the Investigator (Physician's Global Assessment of Improvement).
研究概览
简要总结
Single-center study to evaluate the safety and efficacy of an investigational version of the enlighten™ 670nm laser for photo-rejuvenation.
详细描述
A single-center prospective, open-label uncontrolled exploratory study to evaluate the safety and efficacy of an investigational version of the enlighten™ 670nm laser for photo-rejuvenation.
Subjects will receive laser treatments, and will be followed at 12 weeks post-final treatment. In addition, after each treatment, subjects will complete a 3 day post treatment phone follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Female or Male, 18 to 75 years of age (inclusive).
- •Fitzpatrick Skin Type I - VI.
- •Desires photo-rejuvenation of the skin or improvement in the appearance of acne scarring.
- •Subject has visible signs of acne scarring or moderate sun-damaged and/or aging skin in the treatment area with visible areas acne lesions and scars, fine rhytides, lentigines or pigmentation, diffused redness erythema and skin texture
- •Subject must be able to read, understand and sign the Informed Consent Form.
- •Must be willing and able to adhere to the treatment and follow-up schedule and post-treatment care instructions.
- •Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treatment area every day for the duration of the study, including the follow-up period.
- •Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes.
- •Agree to not undergo any other procedure(s), including injectable agents, for skin rejuvenation during the study and has no intention of having such procedures performed during the course of the study.
- •Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant.
排除标准
- •Participation in a clinical trial of another drug, or device administered to the target area, during the study.
- •Any type of prior cosmetic treatment to the target area within 6 months of study participation, such as laser or light-based procedures or surgery.
- •Prior injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler within 6 months of study participation.
- •History of malignant tumors in the target area.
- •Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, large moles.
- •Pregnant and/or breastfeeding.
- •Having an infection, dermatitis or a rash in the treatment area.
- •Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
- •History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
- •History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications per investigator's discretion.
- •History of vitiligo, eczema, or psoriasis.
- •History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
- •History of seizure disorders due to light.
- •Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
- •History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen
- •History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
- •Systemic use of retinoid, such as isotretinoin, as applicable, within 6 months of study participation.
- •Topical use of retinoid, such as isotretinoin, as applicable, on the treatment area within 1 month of participation.
- •Anytime in life, having have used gold therapy (gold salts) for disorders such as rheumatologic disease or lupus.
- •Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
- •Current smoker or history of smoking within 6 months of study participation.
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
研究组 & 干预措施
Investigational Enlighten Device
Experimental
Laser treatment for facial skin rejuvenation with the experimental enLighten Laser
干预措施: enLighten Laser (Device)
结局指标
主要结局
Degree of Improvement as Assessed by the Investigator (Physician's Global Assessment of Improvement).
时间窗: 12 weeks post-final treatment, an average of 4 months
Degree of improvement in the treated area at 12 weeks post-final treatment as assessed by the Investigator (Physician's Global Assessment of Improvement). Higher scores indicate better outcomes 4= Very Significant Clearing 3=Significant Clearing 2= Moderate Clearing 1= Mild Clearing 0= No Clearing
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
早期 1 期
Anti-CD19-CAR-T Cells in Subjects with Relapsed/Refractory B Cell MalignanciesB-Cell MalignancyNCT06532630Shanghai First Song Biotechnology Co., LTD9
撤回
1 期
CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHLB-cell LymphomaNCT04877080920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
招募中
1 期
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic CancerPancreatic CancerNCT06758544Guangdong Provincial People's Hospital18
招募中
2 期
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionCarcinoma, HepatocellularNCT06454578Qilu Hospital of Shandong University30
招募中
1 期
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT05549973Institute of Hematology & Blood Diseases Hospital, China32